Navigation Links
K-State lab gives researchers the tools to study porcine circovirus associated diseases
Date:8/13/2009

Porcine circovirus associated diseases cost pig producers around the world hundreds of millions of dollars each year.

That's why Kansas State University virologists Dick Hesse and Bob Rowland have been working to create new vaccines to tackle such complex diseases.

"Circovirus and its associated diseases continue to emerge around the world," Hesse said. "Both porcine reproductive and respiratory syndrome and circovirus are a worldwide problem and they continue to evolve."

Hesse and Rowland say that because these viruses continue to adapt, the quick development of effective countermeasures like vaccines is critical, as is having the facilities in which to test the vaccine in a timely fashion.

Later this month, they will begin testing their next-generation vaccine against circovirus at K-State's Biosecurity Research Institute, or BRI, in Pat Roberts Hall.

The vaccination experiment they are preparing is complex and will involve simultaneously testing several groups with porcine circovirus, porcine reproductive and respiratory syndrome, or a combination of the two. Testing vaccine efficacy against viral combinations will be crucial because that's when the most severe forms of disease occur, according to the researchers.

For the purposes of experimentation, keeping each of the groups separate also will be crucial. The BRI is designed so that research on a multitude of agents can take place in rooms adjacent to each other so there is no cross contamination.

"The viruses that we are using have some very unique properties that make containment difficult. In the field, part of the challenge presented by circovirus is that it is easily spread," Rowland said. "We have a lot of experimental groups and under normal circumstances when you are working with infectious disease, it's difficult to prevent cross contamination."

Without the BRI, Hesse and Rowland would have to go elsewhere to conduct an experiment of this scale. They said the ability to do the research at the BRI will mean that the remedies for disease can be available to producers sooner.

"The BRI has some unique capabilities and opportunities for our research," Rowland said "As a result of having access to these facilities we can accelerate our work and infectious disease research at K-State."

"This experiment is setting the stage for the future," Hesse said.

K-State's Biosecurity Research Institute is a biosafety level 3 and biosafety level 3 agriculture research facility. Research at the BRI will help scientists develop a deeper understanding of the pathogens and pests that threaten the U.S. animal- and plant-based agricultural systems so that vaccines and other countermeasures may be proactively developed.

Research at the BRI will eventually include pathogens that directly impact humans, such as brucella and various influenza strains, including H1N1.

Though circovirus and porcine reproductive and respiratory syndrome aren't human pathogens, this research will help BRI officials refine their protocols and procedures.

"The development of appropriate practices, procedures and policies are essential to performing quality research at the BRI," said Scott Rusk, director of Pat Roberts Hall. "Each incoming project will have unique requirements. This collaborative process will help us ensure the safety of personnel and promote high-quality research practices."

The existence of the BRI and the nexus of scientific expertise on animal health and disease at K-State were among the primary reasons the U.S. Department of Homeland Security chose to build the National Bio and Agro-Defense Facility in Manhattan.


'/>"/>

Contact: Richard Hesse
dhesse@vet.k-state.edu
785-532-4457
Kansas State University
Source:Eurekalert

Related biology news :

1. Stimulus funding helps K-State biochemist study eyes lens in diabetes, galactosemia patients
2. K-State researchers say after-school programs should promote activity, healthy nutrition
3. K-State researcher, collaborators study virulence of pandemic H1N1 virus
4. K-State plant pathologists develop online teaching modules used globally
5. Researchers from around the globe coming to K-State June 21 for workshop on Fusarium fungus
6. K-State host to workshop on rapid methods to detect microorganisms in food
7. K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses
8. K-State using Second Life island to help high school students learn earth science
9. K-State researchers work with university in Ghana to create biofuels from native tree seeds
10. K-State researchers help Epitopix license the United States first E. coli O157 vaccine for cattle
11. K-State biologist collaborating with researchers in Africa on grassland sustainability, biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology: